Quadrant Capital Group LLC Anavex Life Sciences Corp. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,161 shares of AVXL stock, worth $19,060. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,161
Previous 1,512
42.92%
Holding current value
$19,060
Previous $8,000
187.5%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AVXL
# of Institutions
188Shares Held
29.2MCall Options Held
894KPut Options Held
821K-
Black Rock Inc. New York, NY6.39MShares$56.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.68MShares$41.3 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$21.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.87MShares$16.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.13MShares$10 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $687M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...